Comorbidity: addiction and other mental illnesses. by unknown
What Is  
Comorbidity?
from the director:
Comorbidity is a topic that our stakehold-
ers––patients, family members, health 
care professionals, and others––frequently 
ask about. It is also a topic about which 
we have insufficient information, and so it 
remains a research priority for NIDA. This 
Research Report provides information on 
the state of the science in this area. And 
although a variety of diseases commonly 
co-occur with drug abuse and addiction 
(e.g. HIV, hepatitis C, cancer, cardiovascular 
disease), this report focuses only on the 
comorbidity of drug use disorders and other 
mental illnesses.*
To help explain this comorbidity, we need 
to first recognize that drug addiction is a 
mental illness. It is a complex brain disease 
characterized by compulsive, at times 
uncontrollable drug craving, seeking, and 
use despite devastating consequences—
behaviors that stem from drug-induced 
changes in brain structure and function. 
These changes occur in some of the same 
brain areas that are disrupted in various 
other mental disorders, such as depression, 
anxiety, or schizophrenia. It is therefore not 
surprising that population surveys show a 
high rate of co-occurrence, or comorbidity, 
between drug addiction and other mental 
illnesses. Even though we cannot always 
prove a connection or causality, we do 
know that certain mental disorders are  
established risk factors for subsequent 
drug abuse—and vice versa.  
It is often difficult to disentangle the over-
lapping symptoms of drug addiction and 
other mental illnesses, making diagnosis 
and treatment complex. Correct diagno-
sis is critical to ensuring appropriate and 
effective treatment. Ignorance of or failure 
to treat a comorbid disorder can jeopardize 
a patient’s chance of success. We hope 
that our enhanced understanding of the 
common genetic, environmental, and 
neural bases of these disorders—and the 
dissemination of this information—will lead 
to improved treatments for comorbidity and 
will diminish the social stigma that makes 
patients reluctant to seek the treatment 
they need.
Nora D. Volkow, M.D. 
Director 
National Institute on Drug Abuse
Comorbidity: 
Addiction and Other Mental Illnesses
Is there a relationship 
between childhood 
ADHD and later drug 
abuse?  See page 2.
When two disorders or illnesses occur in the same person, simultaneously or sequentially, they are called comorbid. Comorbidity also implies 
interactions between the illnesses that affect the course and 
prognosis of both. 
*Drug abuse and drug dependence, or addiction, are considered drug use disorders—a 
subgroup of mental disorders—when they meet the diagnostic criteria delineated in the 
Diagnostic and Statistical Manual of Mental Disorders (DSM). Drug dependence, as DSM 
defines it, is synonymous with the term “addiction,” which will be used preferentially in 
this report. Since the focus of this report is on comorbid drug use disorders and other 
mental illnesses, the terms “mental illness”/“mental disorders” will refer here to disor-
ders other than substance use, such as depression, schizophrenia, anxiety, and mania. 
The terms “dual diagnosis,” “mentally ill chemical abuser,” and “co-occurrence” are also 
used to refer to drug use disorders that are comorbid with other mental illnesses. 
continued inside
Childhood ADHD 
and Later Drug 
Problems
Numerous studies have docu-
mented an increased risk for 
drug use disorders in youth with 
untreated ADHD, although some 
suggest that only a subset of 
these individuals are vulnerable: 
those with comorbid conduct 
disorders. Given this linkage, it is 
important to determine whether 
effective treatment of ADHD 
could prevent subsequent drug 
abuse and associated behavioral 
problems. Treatment of childhood 
ADHD with stimulant medications 
such as methylphenidate or am-
phetamine reduces the impulsive 
behavior, fidgeting, and inability 
to concentrate that characterize 
ADHD. However, some physicians 
and parents have expressed con-
cern that treating childhood ADHD 
with stimulants might increase a 
child’s vulnerability to drug abuse 
later in life. Recent reviews of 
long-term studies of children with 
ADHD who received stimulant 
therapy found no evidence for 
this increase. However, most of 
these studies have methodological 
limitations, including small sample 
sizes and nonrandomized study 
designs, indicating that more  
research is needed, particularly  
in adolescents.
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Is Drug Addiction 
a Mental Illness?
Yes, because addiction changes 
the brain in fundamental ways, 
disturbing a person’s normal hi-
erarchy of needs and desires and 
substituting new priorities con-
nected with procuring and using 
the drug. The resulting compulsive 
behaviors that override the abil-
ity to control impulses despite the 
consequences are similar to hall-
marks of other mental illnesses.  
In fact, the Diagnostic and 
Statistical Manual of Mental 
Disorders (DSM), the definitive 
resource of diagnostic criteria 
for all mental disorders, includes 
criteria for drug use disorders, 
distinguishing between two types: 
drug abuse and drug dependence. 
Drug dependence is synonymous 
with addiction. By comparison, 
the criteria for drug abuse hinge 
on the harmful consequences of 
repeated use but do not include 
the compulsive use, tolerance (i.e., 
needing higher doses to achieve 
the same effect), or withdrawal 
(i.e., symptoms that occur when 
use is stopped) that can be signs  
of addiction.
How Common 
Are Comorbid 
Drug Use and 
Other Mental 
Disorders?
Many people who regularly abuse 
drugs are also diagnosed with 
mental disorders and vice versa. 
The high prevalence of this co-
morbidity has been documented 
in multiple national population 
surveys since the 1980s. Data 
show that persons diagnosed with 
mood or anxiety disorders were 
about twice as likely to suffer also 
from a drug use disorder (abuse 
or dependence) compared with 
respondents in general. The same 
was true for those diagnosed with 
an antisocial syndrome, such as 
antisocial personality or conduct 
disorder. Similarly, persons diag-
nosed with drug disorders were 
roughly twice as likely to  
suffer also from mood and  
anxiety disorders (see page 3, 
“Overlapping Conditions— 
Shared Vulnerability”).
Gender is also a factor in the 
specific patterns of observed co-
morbidities. For example, the 
overall rates of abuse and depen-
dence for most drugs tend to be 
higher among males than females, 
and males are more likely to suf-
fer also from antisocial personal-
ity disorder. In contrast, women 
have higher rates of amphetamine 
dependence and higher rates of 
mood and anxiety disorders. 
Addiction 
changes the 
brain, disturbing 
the normal 
hierarchy of 
needs and desires.
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Why Do Drug Use 
Disorders Often  
Co-Occur With 
Other Mental 
Illnesses?
The high prevalence of comorbidity 
between drug use disorders and other 
mental illnesses does not mean that  
one caused the other, even if it appeared 
first. In fact, establishing causality or 
directionality is difficult for several 
reasons. Some symptoms of a mental 
disorder may not be recognized until the 
illness has substantially progressed, and 
imperfect recollections of when drug 
use/abuse started can also present  
timing issues. Still, three scenarios  
deserve consideration:
1. Drugs of abuse can cause abusers to 
experience one or more symptoms of 
another mental illness. The increased 
risk of psychosis in some marijuana 
abusers has been offered as evidence 
for this possibility.  
2. Mental illnesses can lead to drug 
abuse. Individuals with overt, mild, 
or even subclinical mental disorders 
may abuse drugs as a form of self-
medication. For example, the use of 
tobacco products by patients with 
schizophrenia is believed to lessen the 
symptoms of the disease and improve 
cognition (see page 4, “Smoking and 
Schizophrenia: Self-Medication or 
Shared Brain Circuitry?”).
3. Both drug use disorders and other 
mental illnesses are caused by over-
lapping factors such as underlying 
brain deficits, genetic vulnerabilities, 
and/or early exposure to stress or 
trauma. 
All three scenarios probably  
contribute, in varying degrees, to how  
and whether specific comorbidities 
manifest themselves. 
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Because mood disorders 
increase vulnerability to 
drug abuse and addiction, 
the diagnosis and treat-
ment of the mood disor-
der can reduce the risk 
of subsequent drug use. 
Because the inverse may 
also be true, the diagnosis 
and treatment of drug use 
disorders may reduce the 
risk of developing other 
mental illnesses and, if 
they do occur, lessen their 
severity or make them 
more amenable to effec-
tive treatment. Finally,   
because more than 40 
percent of the cigarettes 
smoked in this country 
are smoked by individuals 
with a psychiatric disorder, 
such as major depressive 
disorder; alcoholism; post-
traumatic stress disorder 
(PTSD); schizophrenia; or 
bipolar disorder, smoking 
by patients with mental  
illness contributes greatly 
to their increased morbid-
ity and mortality. 
Higher Prevalence of Mental Disorders 
Among Patients With Drug Use Disorders
Overlapping Conditions—Shared Vulnerability
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Data in top two graphs reprinted from the National Epidemiologic Survey on Alcohol and Related Conditions (Conway et al., 2006).  
Data in bottom graph from the 1989 U.S. National Health Interview Survey (Lasser et al., 2000).
Higher Prevalence Smoking Among  
Patients With Mental Disorders
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Patients with schizophrenia have higher rates of alcohol, tobacco,  
and other drug abuse than the general population. Based on nationally 
representative survey data, 41 percent of respondents with past-month 
mental illnesses are current smokers, which is about double the rate of 
those with no mental illness. In clinical samples, the rate of smoking in 
patients with schizophrenia has ranged as high as 90 percent. 
 Various self-medication hypotheses have been proposed to explain 
the strong association between schizophrenia and smoking, although 
none have yet been confirmed. Most of these relate to the nicotine 
contained in tobacco products: Nicotine may help compensate for 
some of the cognitive impairments produced by the disorder and may 
counteract psychotic symptoms or alleviate unpleasant side effects of 
antipsychotic medications. Nicotine or smoking behavior may also help 
people with schizophrenia deal with the anxiety and social stigma of 
their disease. 
Research on how both nicotine and schizophrenia affect the brain has 
generated other possible explanations for the high rate of smoking 
among people with schizophrenia: The presence of abnormalities in 
particular circuits of the brain may predispose individuals to schizophre-
nia; increase the rewarding effects of drugs like nicotine; or reduce 
an individual’s ability to quit smoking. The involvement of common 
mechanisms is consistent with the observation that both nicotine and 
the medication clozapine (which also acts at nicotine receptors) can 
improve attention and working memory in an animal model of  
schizophrenia. Clozapine is effective in treating individuals with schizo-
phrenia. It also reduces their smoking levels. Understanding how and 
why patients with schizophrenia use nicotine is likely to help us de-
velop new treatments for both schizophrenia and nicotine dependence.
Smoking and Schizophrenia: Self-
Medication or Shared Brain Circuitry?
Common Factors 
Overlapping Genetic Vulner-
abilities. A particularly active area 
of comorbidity research involves 
the search for genes that might 
predispose individuals to develop 
both addiction and other mental 
illnesses, or to have a greater risk 
of a second disorder occurring after 
the first appears. It is estimated that 
40–60 percent of an individual’s 
vulnerability to addiction is at-
tributable to genetics; most of this 
vulnerability arises from complex 
interactions among multiple genes 
and from genetic interactions with 
environmental influences. In some 
instances, a gene product may act 
directly, as when a protein influ-
ences how a person responds to a 
drug (e.g., whether the drug experi-
ence is pleasurable or not) or how 
long a drug remains in the body. 
But genes can also act indirectly by 
altering how an individual responds 
to stress or by increasing the likeli-
hood of risk-taking and novelty-
seeking behaviors, which could 
influence the development of both 
drug use disorders and other mental 
illnesses. Several regions of the hu-
man genome have been linked to 
increased risk of both, including as-
sociations with greater vulnerability 
to adolescent drug dependence and 
conduct disorders. 
Involvement of Similar Brain 
Regions. Some areas of the brain 
are affected by both drug use dis-
orders and other mental illnesses. 
For example, the circuits in the 
brain that use the neurotransmitter 
dopamine—a chemical that carries 
messages from one neuron to an-
other—are typically affected by ad-
dictive substances and may also be 
involved in depression, schizophre-
nia, and other psychiatric disorders. 
The rate of smoking 
in patients with 
schizophrenia has 
ranged as high as  
90 percent.
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 Indeed, some antidepressants and 
essentially all antipsychotic medi-
cations target the regulation of 
dopamine in this system directly, 
whereas others may have indirect 
effects. Importantly, dopamine 
pathways have also been impli-
cated in the way in which stress 
can increase vulnerability to drug 
addiction. Stress is also a known 
risk factor for a range of mental 
disorders and therefore provides 
one likely common neurobiological 
link between the disease processes 
of addiction and those of other 
mental disorders. 
The overlap of brain areas in-
volved in both drug use disorders 
and other mental illnesses sug-
gests that brain changes stemming 
from one may affect the other. For 
example, drug abuse that precedes 
the first symptoms of a mental 
illness may produce changes in 
brain structure and function that 
kindle an underlying propensity 
to develop that mental illness. If 
the mental disorder develops first, 
associated changes in brain activ-
ity may increase the vulnerability 
to abusing substances by enhanc-
ing their positive effects, reducing 
awareness of their negative effects, 
or alleviating the unpleasant  
effects associated with the mental 
disorder or the medication used to 
treat it. 
The Influence of 
Developmental Stage
Adolescence—A Vulnerable 
Time. Although drug abuse and 
addiction can happen at any time 
during a person’s life, drug use 
typically starts in adolescence, 
a period when the first signs of 
mental illness commonly appear. 
It is therefore not surprising that 
comorbid disorders can already 
be seen among youth. Significant 
changes in the brain occur during 
adolescence, which may enhance 
vulnerability to drug use and the 
development of addiction and other 
mental disorders. Drugs of abuse 
affect brain circuits involved in 
reward, decisionmaking, learning 
and memory, and behavioral 
control, all of which are still 
maturing into early adulthood. 
Thus, understanding the long-term 
impact of early drug exposure is a 
critical area of comorbidity research. 
Early Occurrence Increases 
Later Risk. Strong evidence has 
emerged showing early drug use to 
be a risk factor for later substance 
abuse problems; additional find-
ings suggest that it may also be a 
risk factor for the later occurrence 
of other mental illnesses. How-
ever, this link is not necessarily a 
simple one and may hinge upon 
genetic vulnerability, psychosocial 
experiences, and/or general en-
vironmental influences. A recent 
study highlights this complexity, 
The brain continues to develop into 
adulthood and undergoes dramatic 
changes during adolescence.
One of the brain areas still maturing during adolescence is the prefrontal 
cortex—the part of the brain that enables us to assess situations, make 
sound decisions, and keep our emotions and desires under control. The 
fact that this critical part of an adolescent’s brain is still a work in progress 
puts them at increased risk for poor decisions (such as trying drugs or 
continuing abuse). Thus, introducing drugs while the brain is still develop-
ing may have profound and long-lasting consequences. 
5 20
AGES
NIDA Research Report Series 5
with the finding that frequent  
marijuana use during adolescence 
can increase the risk of psychosis 
in adulthood, but only in individu-
als who carry a particular gene 
variant (see sidebar, “The Influ-
ence of Adolescent Marijuana Use 
on Adult Psychosis Is Affected by  
Genetic Variables”). 
It is also true that having a 
mental disorder in childhood 
or adolescence can increase the 
risk of later drug abuse prob-
lems, as frequently occurs with 
conduct disorder and untreated 
attention-deficit hyperactivity 
disorder (ADHD). This presents a 
challenge when treating children 
with ADHD, since effective treat-
ment often involves prescribing 
stimulant medications with abuse 
potential. This issue has generated 
strong interest from the research 
community, and although the re-
sults are not yet conclusive, most 
studies suggest that ADHD medi-
cations do not increase the risk of 
drug abuse among children with 
ADHD (see page 2, “Childhood 
ADHD and Later Drug Problems”). 
Regardless of how comorbidity 
develops, it is common in youth 
as well as adults. Given the high 
prevalence of comorbid mental 
disorders and their likely ad-
verse impact on substance abuse 
treatment outcomes, drug abuse 
programs for adolescents should 
include screening and, if needed, 
treatment for comorbid mental 
disorders.
The high rate of comorbidity between drug abuse 
and addiction and other mental disorders argues for a 
comprehensive approach to intervention that identifies, 
evaluates, and treats each disorder concurrently.
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The Influence of Adolescent 
Marijuana Use on Adult Psychosis 
Is Affected by Genetic Variables
Source: Caspi A, Moffitt TE, Cannon M, et al., 2005.
The above figure shows that variations in a gene can affect the likelihood 
of developing psychosis in adulthood following exposure to cannabis. 
The Catechol-O-Methyltransferase gene regulates an enzyme that breaks 
down dopamine, a brain chemical involved in schizophrenia. It comes in 
two forms: Met and Val. Individuals with one or two copies of the Val  
variant have a higher risk of developing schizophrenic-type disorders if 
they used cannabis during adolescence (dark bars). Those with only the 
Met variant were unaffected by cannabis use. These findings hint at the 
complexity of factors that contribute to comorbid conditions; however, 
more research is needed.
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How Can 
Comorbidity Be 
Diagnosed?
The high rate of comorbidity 
between drug use disorders and 
other mental illnesses argues for a 
comprehensive approach to inter-
vention that identifies, evaluates, 
and treats each disorder concur-
rently. The needed approach calls 
for broad assessment tools that 
are less likely to result in a missed 
diagnosis. Accordingly, patients 
entering treatment for psychiatric 
illnesses should also be screened 
for substance use disorders and 
vice versa. Accurate diagnosis 
is complicated, however, by the 
similarities between drug-related 
symptoms such as withdrawal 
and those of potentially comorbid 
mental disorders. Thus, when 
people who abuse drugs enter 
treatment, it may be necessary to 
observe them after a period of ab-
stinence in order to distinguish the 
effects of substance intoxication or 
withdrawal from the symptoms of 
comorbid mental disorders—this 
would allow for a more accurate 
diagnosis.
How Should 
Comorbid 
Conditions Be 
Treated?
A fundamental principle emerging 
from scientific research is the 
need to treat comorbid conditions 
concurrently—which can be a 
difficult proposition (see page 
9, “Barriers to Comprehensive 
Treatment of Comorbidity”). 
Patients who have both a drug 
 
Exposure to 
Traumatic Events 
Puts People at 
Higher Risk of 
Substance Use 
Disorders.
Emotionally traumatized people 
are at much higher risk of abusing 
licit, illicit, and prescription drugs. 
The strong association between 
PTSD and substance abuse is par-
ticularly frequent and devastating 
among military veterans, among 
whom 38,000 PTSD cases have 
been documented in the past 5 
years alone. Epidemiological stud-
ies suggest that as many as half 
of them may have a co-occurring 
substance use disorder (SUD). 
The growing incidence of PTSD 
among returning veterans poses 
an enormous challenge for a 
health care system in which PTSD 
programs don’t accept individuals 
with active SUDs while traditional 
SUD clinics defer the treatment of 
trauma-related issues. However, 
there are treatment options for 
PTSD and SUD at different stages 
of clinical validation; these include 
various combinations of psycho-
social (e.g., exposure therapy) and 
pharmacologic (e.g., mood stabiliz-
ers, antianxiolitics, and antidepres-
sants) interventions. However, 
more research is urgently needed 
to identify the best treatment 
strategies for addressing PTSD 
comorbidities, in particular depres-
sion and SUD, and to explore the 
notion that different treatments 
might be needed in response to 
civilian vs. combat PTSD.
use disorder and another mental 
illness often exhibit symptoms that 
are more persistent, severe, and 
resistant to treatment compared 
with patients who have either 
disorder alone. Nevertheless, 
steady progress is being made 
through research on new and 
existing treatment options 
for comorbidity and through 
health services research on 
implementation of appropriate 
screening and treatment within 
a variety of settings (e.g., NIDA’s 
Criminal Justice Drug Abuse 
Treatment Studies [CJ-DATS]).  
Medications
Effective medications exist for 
treating opioid, alcohol, and nico-
tine addiction and for alleviating 
the symptoms of many other 
mental disorders. Most of these 
medications have not been studied 
in patients with comorbidities, 
although some may prove effective 
for treating comorbid conditions. 
For example, preliminary results 
of a recent study point to the po-
tential of using divalproex (trade 
name: Depakote)—an anticon-
vulsant commonly used to treat 
bipolar disorder—to treat patients 
with comorbid bipolar disorder 
and primary cocaine dependence. 
Other evidence suggests that  
bupropion (trade names: Well-
butrin, Zyban), approved for 
treating depression and nicotine 
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Examples of Promising Behavioral Therapies 
for Patients With Comorbid Conditions
Adults
Therapeutic Communities (TCs) 
TCs focus on the “resocialization” of 
the individual and use broad-based 
community programs as active compo-
nents of treatment. TCs are particularly 
well suited to deal with criminal justice 
inmates, individuals with vocational 
deficits, women who need special 
protections from harsh social environ-
ments, vulnerable or neglected youth, 
and homeless individuals. In addition, 
some evidence suggests the utility of 
incorporating TCs for adolescents who 
have been in treatment for substance   
abuse and related problems.
Assertive Community Treatment 
(ACT)
ACT programs integrate the behav-
ioral treatment of other severe mental 
disorders, such as schizophrenia, and 
co-occurring substance use disorders. 
ACT is differentiated from other forms 
of case management through factors 
such as a smaller caseload size, team 
management, outreach emphasis, a 
highly individualized approach, and an 
assertive approach to maintaining con-
tact with patients. 
Dialectical Behavior Therapy (DBT)
DBT is designed specifically to reduce 
self-harm behaviors (such as self- 
mutilation and suicidal attempts, 
thoughts, or urges) and drug abuse. It is 
one of the few treatments that are effec-
tive for individuals who meet the criteria 
for borderline personality disorder.
Exposure Therapy
Exposure therapy is a behavioral 
treatment for some anxiety disorders 
(phobias, post-traumatic stress disorder 
[PTSD]) that involves repeated exposure 
to or confrontation with a feared situation, 
object, traumatic event, or memory. 
This exposure can be real, visualized, or 
simulated, and always is contained in 
a controlled therapeutic environment. 
The goal is to desensitize patients to the 
triggering stimuli and help them learn 
to cope, eventually reducing or even 
eliminating symptoms. Several studies 
suggest that exposure therapy may be 
helpful for individuals with comorbid 
PTSD and cocaine addiction, although 
retention in treatment is difficult. 
Integrated Group Therapy (IGT)
IGT is a new treatment developed spe-
cifically for patients with bipolar disorder 
and drug addiction, designed to address 
both problems simultaneously.
Adolescents
Multisystemic Therapy (MST)
MST targets key factors (attitudes, fam-
ily, peer pressure, school and neighbor-
hood culture) associated with serious 
antisocial behavior in children and 
adolescents who abuse drugs.
Brief Strategic Family Therapy (BSFT) 
BSFT targets family interactions that are 
thought to maintain or exacerbate ado-
lescent drug abuse and other co-occur-
ring problem behaviors. These problem 
behaviors include conduct problems 
at home and at school, oppositional 
behavior, delinquency, associating with 
antisocial peers, aggressive and violent 
behavior, and risky sexual behaviors.
Cognitive-Behavioral Therapy (CBT) 
CBT is designed to modify harmful 
beliefs and maladaptive behaviors. CBT 
is the most effective psychotherapy for 
children and adolescents with anxiety 
and mood disorders, and also shows 
strong efficacy for substance abusers. 
(CBT is also effective for adult popula-
tions suffering from drug use disor-
ders and a range of other psychiatric 
problems.)  
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Barriers to Comprehensive 
Treatment of Comorbidity
Although research supports the need for comprehensive treatment to  
address comorbidity, provision of such treatment can be problematic for  
a number of reasons:  
•	 In	the	United	States	different	treatment	systems	address	drug	use	
disorders and other mental illnesses separately. Physicians are most 
often the front line of treatment for mental disorders, whereas drug 
abuse treatment is provided in assorted venues by a mix of health 
care professionals with different backgrounds. Thus, neither system 
may have sufficiently broad expertise to address the full range of 
problems presented by patients. People also use these health care 
systems differently, depending on insurance coverage and social fac-
tors. For example, when suffering from substance abuse and mental 
illness comorbidities, women more often pursue treatment services 
for mental health problems, whereas men tend to seek help through 
substance abuse treatment channels. 
•	 A	lingering	bias	remains	in	some	substance	abuse	treatment	centers	
against using any medications, including those necessary to treat 
serious mental disorders such as depression. Additionally, many 
substance abuse treatment programs do not employ professionals 
qualified to prescribe, dispense, and monitor medications.  
•	 Many	of	those	needing	treatment	are	in	the	criminal	justice	system.	 
It is estimated that about 75 percent of offenders in State and local 
prisons and jails have a mental health problem comorbid with sub-
stance abuse or addiction. However, adequate treatment services for 
both drug use disorders and other mental illnesses are greatly lacking  
within these settings. While treatment provision may be burdensome 
for the criminal justice system, it offers an opportunity to positively 
affect the public’s health and safety. Treatment of comorbid disorders 
can reduce not only associated medical complications, but also  
negative social outcomes by mitigating against a return to criminal 
behavior and reincarceration.    
dependence, might also help re-
duce craving and use of metham-
phetamine. Most medications have 
not been well studied in comorbid 
populations or in populations 
taking other psychoactive medica-
tions. Therefore, more research 
is needed to fully understand and 
assess the actions of combined or 
dually effective medications. 
Behavioral Therapies  
Behavioral treatment (alone or in 
combination with medications) 
is the cornerstone to successful 
outcomes for many individuals 
with drug use disorders or other 
mental illnesses. And while be-
havior therapies continue to be 
evaluated for use in comorbid 
populations, several strategies 
have shown promise for treating 
specific comorbid conditions (see 
page 8, “Examples of Promising 
Behavioral Therapies for Patients 
With Comorbid Conditions”). 
Most clinicians and research-
ers agree that broad spectrum 
diagnosis and concurrent therapy 
will lead to more positive out-
comes for patients with comorbid 
conditions. Preliminary findings 
support this notion, but research 
is needed to identify the most ef-
fective therapies (especially stud-
ies focused on adolescents).
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Glossary 
Addiction: A chronic, relapsing 
disease characterized by compulsive 
drug seeking and abuse in spite of 
known adverse consequences, and 
by functional, sometimes long-lasting 
changes in the brain. 
Antisocial Personality Disorder: A 
disorder characterized by antisocial 
behaviors that involve pervasive dis-
regard for and violation of the rights, 
feelings, and safety of others, begin-
ning in childhood or the early teenage 
years and continuing into adulthood. 
Attention-Deficit Hyperactiv-
ity Disorder (ADHD): A disorder 
characterized by inattentiveness and/
or hyperactivity and impulsivity at a 
level far greater than others of the 
same age. 
Anxiety Disorders: Varied dis-
orders that involve excessive or 
inappropriate feelings of anxiety or 
worry. Examples are panic disorder, 
post-traumatic stress disorder, social 
phobia, and others.
Bipolar Disorder: A mood disorder 
characterized by alternating episodes 
of depression and mania or hypo-
mania.
Comorbidity: The occurrence of two 
disorders or illnesses in the same 
person, either at the same time 
(co-occurring comorbid conditions) or 
with a time difference between the 
initial occurrence of one and the ini-
tial occurrence of the other (sequen-
tially comorbid conditions). 
Dopamine: A chemical (neurotrans-
mitter) found in parts of the brain 
responsible for reward, motivation, 
and movement. 
Dual Diagnosis/Mentally Ill Chemi-
cal Abuser (MICA): Other terms 
used to describe the comorbidity of a 
drug use disorder and another mental 
illness.
Depression: A disorder marked by 
sadness, inactivity, difficulty with 
thinking and concentration, signifi-
cant increase or decrease in appetite 
and time spent sleeping, feelings 
of dejection and hopelessness, and 
sometimes, suicidal thoughts or an 
attempt to commit suicide.
Major Depressive Disorder: A mood 
disorder having a clinical course of 
one or more serious depression 
episodes that last 2 or more weeks. 
Episodes are characterized by a loss 
of interest or pleasure in almost all 
activities; disturbances in appetite, 
sleep, or psychomotor functioning; 
a decrease in energy; difficulties in 
thinking or making decisions; loss of 
self-esteem or feelings of guilt; and 
suicidal thoughts or attempts.
Mania: A mood disorder character-
ized by abnormally and persistently 
elevated, expansive, or irritable 
mood; mental and physical hyper-
activity; and/or disorganization of 
behavior.
Mental Disorder: A mental condi-
tion marked primarily by sufficient 
disorganization of personality, mind, 
and emotions to seriously impair the 
normal psychological or behavioral 
functioning of the individual.  
Addiction is a mental disorder.
Neurotransmitters: The brain’s 
chemical messengers used to trans-
mit information between neurons.
Post-Traumatic Stress Disorder 
(PTSD): A disorder that develops 
after exposure to a highly stress-
ful event (e.g., wartime combat, 
physical violence, or natural disaster). 
Symptoms include re-experiencing 
the trauma through flashbacks or 
recurrent nightmares, hypervigilance 
and difficulty sleeping, and avoidance 
of reminders of the event.
Psychosis: A serious mental disorder 
(e.g., schizophrenia) characterized by 
defective or lost contact with reality. 
Symptoms often include hallucina-
tions or delusions.
Schizophrenia: A psychotic disor-
der characterized by symptoms that 
fall into two categories: (1) positive 
symptoms, such as distortions in 
thoughts (delusions), perception (hal-
lucinations), and language and think-
ing and (2) negative symptoms, such 
as flattened emotional responses and 
decreased goal-directed behavior. 
Self-Medication: The use of a sub-
stance to lessen the negative effects 
of stress, anxiety, or other mental 
disorders (or side effects of their 
pharmacotherapy). Self-medication 
may lead to addiction and other  
drug- or alcohol-related problems.
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Where can I get more scientific 
information on comorbid addiction 
and other mental illnesses?
To learn more about drug abuse 
and other mental illnesses, con-
tact….
Where Can I Get More Scientific Information on 
Comorbid Addiction and Other Mental Illnesses?
To learn more about drug use disorders and other 
mental illnesses, or to order materials on these topics 
free of charge in English or Spanish, visit the NIDA 
Web site at www.drugabuse.gov or contact the  
DrugPubs Research Dissemination Center at  
877-NIDA-NIH (877-643-2644;  
TTY/TDD: 240-645-0228).
What’s New on the NIDA Web Site
• Information on drugs of abuse
• Publications and communications (including  
NIDA Notes and Addiction Science & Clinical  
Practice journal)
• Calendar of events
• Links to NIDA organizational units
• Funding information (including program  
announcements and deadlines)
• International activities
• Links to related Web sites (access to Web sites  
of many other organizations in the field)
NIDA Web Sites
drugabuse.gov
backtoschool.drugabuse.gov
smoking.drugabuse.gov
hiv.drugabuse.gov
marijuana-info.org
clubdrugs.gov
steroidabuse.gov
teens.drugabuse.gov
inhalants.drugabuse.gov
Other Web Sites
Information on drug abuse and other mental illnesses 
is also available through these other Web sites:
• National Institute of Mental Health:  
www.nimh.nih.gov
• National Institute on Alcohol Abuse and  
Alcoholism: www.niaaa.nih.gov
• Substance Abuse and Mental Health Services  
Administration Health Information Network:  
www.samhsa.gov/shin
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